Effects  of rosuvastatin treatment  on coronary artery ectasia in different patient age groups

Background: This study investigated the relationship between coronary artery ectasia (CAE) and serum levels of high-sensitivity C-reactive protein (Hs-CRP) to test our hypothesis that patient age is associated with the efficacy of anti-inflammatory therapy in CAE. Method: We conducted a prospective analysis of 217 patients with CAE treated at the Department of Cardiology, Shanghai East Hospital, Shanghai East Hospital (Ji'an Campus), Cardiovascular Medicine of Baoshan People’s Hospital of Yunnan Province, from January 1, 2015, to July 30, 2019. Baseline data of patients, including sex, age, hypertension, hyperlipidemia, and diabetes, were collected from patient medical records. Study participants were grouped by age: CAE-A (age ≤50 years); CAE-B (50 years 70). Results: All CAE patients received oral rosuvastatin therapy (10 mg, QN quaque night) and maintained good follow-up, with a loss rate of 0.0% at the 6-month follow-up. The control group (NC Group, n = 73, with normal coronary arteries) received regular symptom-relieving treatments. Among these four groups, the inflammatory markers were significantly higher in patients with CAE than in the NC Group. The inflammatory markers in the CAE-A group were higher than in the CAE-B group, which were higher than the CAE-C group. Follow-up after 6 months of rosuvastatin therapy showed a significantly greater reduction in Hs-CRP and interleukin-6 levels in the CAE-A group than the CAE-B group, which, again, were higher than the CAE-C group. Conclusions: Anti-inflammatory therapy using rosuvastatin was more effective in younger CAE patients, indicating the need for early statin therapy in CAE patients.